JG
HZNP

Jefferies Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Jefferies Group’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$14.7M Buy
237,185
+230,528
+3,463% +$16.1M 0.12% 125
2022
Q2 		$531K Sell
6,657
-15,517
-70% -$1.47M ﹤0.01% 969
2022
Q1 		$2.33M Sell
22,174
-43,571
-66% -$4.25M 0.01% 637
2021
Q4 		$7.08M Buy
65,745
+8,076
+14% +$881K 0.04% 363
2021
Q3 		$6.32M Buy
57,669
+47,703
+479% +$4.95M 0.05% 382
2021
Q2 		$933K Buy
9,966
+3,000
+43% +$276K 0.01% 1012
2021
Q1 		$641K Sell
6,966
-4,205
-38% -$355K 0.01% 1054
2020
Q4 		$817K Sell
11,171
-52,353
-82% -$3.89M 0.01% 997
2020
Q3 		$4.93M Sell
63,524
-1,476
-2% -$102K 0.05% 293
2020
Q2 		$3.61K Buy
65,000
+53,320
+457% +$2.28M 0.04% 356
2020
Q1 		$346K Buy
+11,680
New +$395K ﹤0.01% 1476
2019
Q3 		– Sell
-11,160
Closed -$269K – 3254
2019
Q2 		$269K Sell
11,160
-10,914
-49% -$277K ﹤0.01% 1979
2019
Q1 		$583K Buy
22,074
+3,744
+20% +$88.7K ﹤0.01% 1523
2018
Q4 		$358K Sell
18,330
-6,200
-25% -$122K ﹤0.01% 1589
2018
Q3 		$480K Sell
24,530
-18,306
-43% -$348K ﹤0.01% 1648
2018
Q2 		$709K Buy
+42,836
New +$653K ﹤0.01% 1424
2017
Q1 		– Sell
-41,143
Closed -$666K – 2799
2016
Q4 		$666K Buy
41,143
+5,900
+17% +$107K ﹤0.01% 1475
2016
Q3 		$639K Buy
+35,243
New +$689K ﹤0.01% 1506
2016
Q1 		– Sell
-35,709
Closed -$625K – 2730
2015
Q4 		$774K Sell
35,709
-20,991
-37% -$409K ﹤0.01% 1296
2015
Q3 		$1.12M Sell
56,700
-362,133
-86% -$11.4M 0.01% 1159
2015
Q2 		$14.6M Buy
+418,833
New +$12.8M 0.08% 215
2014
Q4 		– Sell
-28,236
Closed -$353K – 2500
2014
Q3 		$347K Buy
28,236
+28,148
+31,986% +$327K ﹤0.01% 1524
2014
Q2 		$1K Sell
88
-60
-41% -$856 ﹤0.01% 2024
2014
Q1 		$2K Buy
+148
New +$1.67K ﹤0.01% 1971

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Jefferies Group's HZNP Position: Q3 2022 in Review

Jefferies Group increased its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 3,463% in Q3 2022, buying an estimated $16.1M and bringing the position to 237,185 shares worth $14.7M. The position accounts for 0.12% of the portfolio, ranked #125.

Jefferies Group first reported a position in HZNP in Q1 2014 and has held it in 24 quarters since. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

  • Jefferies Group held 237,185 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $14.7M as of Q3 2022.
  • Jefferies Group bought 230,528 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $16.1M.
  • Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.12% of Jefferies Group's portfolio in Q3 2022, its #125 holding.
  • Jefferies Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2014 and has held it in 24 quarters since.
  • 530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.